{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-26-000005","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.744241+00:00","generated_at":"2026-05-16T10:47:38.136966+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PacBio Q4 revenue $44.6M (+14% YoY); full year $160M (+4%); record consumables","bullets":["Q4 2025 revenue ~$44.6M vs $39.2M YoY; full year ~$160M vs $154M.","Instrument revenue Q4 ~$17.3M (Q4'24 $15.3M); consumables ~$21.6M (Q4'24 $18.8M) a record.","Vega placements 42 in Q4 vs 7 a year ago; Revio placements 21 vs 23.","Ending cash $279.5M vs $389.9M; management cites reduced cash burn and SPRQ-Nx catalyst.","PacBio presents at J.P. Morgan Healthcare Conference on Jan 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-26-000005","json":"https://secwatch.observer/filing/0001299130-26-000005.json","markdown":"https://secwatch.observer/filing/0001299130-26-000005.md","text":"https://secwatch.observer/filing/0001299130-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000005/0001299130-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913026000005/pacb-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:47:38.136966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}